Influenza infection, Acute myocardial Infarction, Flu Shot during COVID-19 Pandemic in US population. A Review of Literature.

Influenza is a major cause of hospitalization in all age groups but can cause more severe infections in specific high-risk population. Novel Corona Virus Disease 2019 (COVID-19) pandemic and Influenza virus infection cause similar illness and coexist. Cardiovascular complications due to influenza are important causes of morbidity and mortality in the US, especially in the elderly population (aged more than 65 years). Acute Myocardial Infarction (AMI) is the most serious among the cardiovascular causes of mortality following the attack of influenza, mainly in patients with various co-morbidities like pre-existing coronary artery disease (CAD), diabetes mellitus (DM), hypertension (HTN), and heart failure (HF). We have reviewed the association between influenza virus infection and AMI and extrapolated the beneficial effects of influenza vaccine in preventing AMI and its grave consequences. We have also highlighted about the importance of flu shot during the COVID-19 pandemic.


Introduction
Influenza complications are important causes of morbidity and mortality in many parts of the world, especially in the elderly population (aged> 65 years). This seems to be on an increasing trend with the increase in life expectancy in the aging population 1 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.14.21260549 doi: medRxiv preprint 4 Objective: The purpose of this article is to provide an updated review on influenza/flu illness and AMI and highlight the role of flu vaccination in times of COVID-19 pandemic.

Data extraction
We searched Medline and Embase using relevant Medical Subject Headings (MeSH) termed influenza or influenza virus or flu or Corona virus, COVID-19, Novel Corona Virus, SARA-CoV-2, flu vaccine, and myocardial infarction or acute myocardial infarction or STEMI/ ACS or heart attack literature published within the last five years with additional filters of human studies and customized articles. The titles and abstracts of all results were reviewed and studies were selected for full-text analysis according to their eligibility criteria. Figure 1.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.14.21260549 doi: medRxiv preprint 5 Figure 1: Flow Diagram of Included Studies

Eligibility criteria
We included human studies on AMI, COVID-19 and influenza or influenza vaccination in adults (age more than or equal to18 years) for full-text analysis. We excluded review articles and case reports.

Quality assessment and data extraction
Authors NB and NN independently performed the study selection, data extraction and quality assessment.in the prevention of AMI associated hospitalization and death.

Prevalence of influenza triggered AMI
Influenza is a trigger for AMI and ischemic heart disease (IHD) particularly in the elderly population 4, 7-9. Warren-Gash et al 10 . performed a multicentre prospective time series study in England, Wales and Hong Kong and found that influenza was associated with increased AMI related hospitalization and death, suggesting this infection as an independent risk factor for AMI 10 . This is further supported by an observational study by Song et al. who too reported that elderly patients suffering from influenza and having other comorbidities such as DM, HF, pre-existing CAD and HTN had higher in-hospital cardiac mortality (fatal cardiac arrest and ventricular arrhythmias) as compared to patients without these risk factors 11 .
A similar association between infection due to influenza virus and AMI was documented by Pearce et al.8 and Kwong et al. 4 substantiated that the influenza virus was a stronger risk factor for the development of AMI than any other virus causing acute respiratory tract infection. A time . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.14.21260549 doi: medRxiv preprint 6 series study by Nguyen et al. found that there was a significant increase in all cause cardiovascular mortality and AMI mortality during the influenza outbreak 1 Guan and colleagues in the recent past stated that cases of AMI were more likely to have positive IgG antibodies to influenza virus A and B as compared to controls; an observation which supported the hypothesis that previous influenza virus infection had a role to play in the development of atherosclerosis, eventually triggering the occurrence of AMI 13 .

Pathogenesis of post-influenza AMI
The precise mechanism for the development of AMI following influenza virus infection is is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.14.21260549 doi: medRxiv preprint  5,19,20 . A study by Nayak et al highlights that, to prevent AMI hospitalizations and mortality following an attack of influenza, prompt administration of influenza vaccine is needed 20 . Huang et al. conducted a cohort study and showed a significant reduction in the risk of ischemic heart disease in elderly patients receiving influenza vaccine 19,20 .
A systematic review by Claret al. also showed that AMI was significantly reduced after influenza vaccination 20 . In a prospective randomized open-ended study by Phrommintikul et al., influenza vaccination was shown to decrease major cardiovascular hospitalizations due to AMI. However, no significant difference was found in the incidence of cardiovascular deaths among vaccine recipient and non-recipient groups 21 .This is further supported in a meta-analysis by Udell et al, however, the difference is statistically non-significant and further studies are (Controls) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.14.21260549 doi: medRxiv preprint warranted to prove the benefit of influenza vaccine in the prevention of cardiovascular mortality, especially in high-risk patients with previous acute coronary syndrome 22 . However, vaccine, by preventing influenza and its associated hospitalizations, in a way could prevent the possibility of AMI triggered by the mechanisms discussed above and also might prevent the associated AMI related mortality.
Just as influenza vaccine prevents the AMI and its associated hospitalizations, COVID-19 vaccine may prevent AMI and associated Cardiovascular hospitalizations 20,23 . We need more studies to comment on these topics. Vaccination should be encouraged to prevent cardiovascular complications and mortality especially among high-risk and elderly patients, in these challaging times of COVID-19 5, 20-26 . pandemic.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.14.21260549 doi: medRxiv preprint